DE60006580D1 - Benzazolderivate und ihre verwendung als jnk modulatoren - Google Patents

Benzazolderivate und ihre verwendung als jnk modulatoren

Info

Publication number
DE60006580D1
DE60006580D1 DE60006580T DE60006580T DE60006580D1 DE 60006580 D1 DE60006580 D1 DE 60006580D1 DE 60006580 T DE60006580 T DE 60006580T DE 60006580 T DE60006580 T DE 60006580T DE 60006580 D1 DE60006580 D1 DE 60006580D1
Authority
DE
Germany
Prior art keywords
benzazole derivatives
jnk modulators
jnk
modulators
benzazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60006580T
Other languages
English (en)
Other versions
DE60006580T2 (de
Inventor
Serge Halazy
Dennis Church
Montserrat Camps
Pascale Gaillard
Jean-Pierre Gotteland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE60006580D1 publication Critical patent/DE60006580D1/de
Application granted granted Critical
Publication of DE60006580T2 publication Critical patent/DE60006580T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60006580T 1999-12-24 2000-12-20 Benzazolderivate und ihre verwendung als jnk modulatoren Expired - Lifetime DE60006580T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99811207 1999-12-24
EP99811207A EP1110957A1 (de) 1999-12-24 1999-12-24 Benzazolderivate und ihre Verwendung als JNK Modulatoren
PCT/EP2000/013006 WO2001047920A1 (en) 1999-12-24 2000-12-20 Benzazole derivatives and their use as jnk modulators

Publications (2)

Publication Number Publication Date
DE60006580D1 true DE60006580D1 (de) 2003-12-18
DE60006580T2 DE60006580T2 (de) 2004-09-16

Family

ID=8243214

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60006580T Expired - Lifetime DE60006580T2 (de) 1999-12-24 2000-12-20 Benzazolderivate und ihre verwendung als jnk modulatoren

Country Status (33)

Country Link
US (2) US7259162B2 (de)
EP (2) EP1110957A1 (de)
JP (1) JP4782344B2 (de)
KR (2) KR20070047853A (de)
CN (1) CN1252067C (de)
AR (1) AR029215A1 (de)
AT (1) ATE254123T1 (de)
AU (1) AU780241B2 (de)
BG (1) BG65986B1 (de)
BR (1) BR0016911A (de)
CA (1) CA2394809C (de)
CZ (1) CZ300984B6 (de)
DE (1) DE60006580T2 (de)
DK (1) DK1240164T3 (de)
EA (1) EA007152B1 (de)
EE (1) EE05456B1 (de)
ES (1) ES2206351T3 (de)
HK (1) HK1055730A1 (de)
HR (1) HRP20020496B1 (de)
HU (1) HU229625B1 (de)
IL (2) IL150346A0 (de)
MX (1) MXPA02006242A (de)
NO (1) NO323146B1 (de)
NZ (1) NZ519423A (de)
PL (1) PL356634A1 (de)
PT (1) PT1240164E (de)
RS (1) RS51008B (de)
SI (1) SI1240164T1 (de)
SK (1) SK287546B6 (de)
TR (2) TR200302320T4 (de)
UA (1) UA73151C2 (de)
WO (1) WO2001047920A1 (de)
ZA (1) ZA200204427B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4535680B2 (ja) 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
DE60230625D1 (de) 2001-07-23 2009-02-12 Serono Lab Arylsulfonamidderivate als hemmer c-jun-terminaler kinasen (jnk)
DE60215042T2 (de) * 2001-12-07 2007-10-04 Applied Research Systems Ars Holding N.V. Benzazole derivate zur behandlung von scleroderma
UA78035C2 (en) * 2002-04-25 2007-02-15 Applied Research Systems Piperazine benzothiazole for treatment of cerebral ischemic disorders or cns disorders
WO2003101968A1 (fr) 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
JP4662764B2 (ja) * 2002-06-14 2011-03-30 メルク セローノ ソシエテ アノニム アゾールメチリデンシアニド誘導体およびそれらのタンパク質キナーゼモジュレーターとしての使用
ES2438967T3 (es) 2002-10-23 2014-01-21 University Of Utah Research Foundation Análisis de fusión de amplicones con colorantes de saturación
CA2524161C (en) * 2003-05-08 2013-01-15 Applied Research Systems Ars Holding N.V. Pyridinyl acetonitriles
CA2534314C (en) * 2003-09-12 2012-11-13 Applied Research Systems Ars Holding N.V. Benzothiazole derivatives for the treatment of diabetes
AU2004272307A1 (en) * 2003-09-12 2005-03-24 Merck Serono Sa Benzoxazole acetonitriles
EP1667995A1 (de) * 2003-09-12 2006-06-14 Applied Research Systems ARS Holding N.V. Benzimidazolacetonitrile
KR20060134198A (ko) * 2004-04-08 2006-12-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｊｎｋ 저해제 및 시클로스포린을 포함하는 조성물
US9657347B2 (en) 2004-04-20 2017-05-23 University of Utah Research Foundation and BioFire Defense, LLC Nucleic acid melting analysis with saturation dyes
US7387887B2 (en) * 2004-04-20 2008-06-17 University Of Utah Research Foundation Nucleic acid melting analysis with saturation dyes
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
EA011614B1 (ru) * 2004-11-17 2009-04-28 Арес Трейдинг С.А. Препараты бензотиазола и их применение
US7973039B2 (en) 2004-12-21 2011-07-05 Merck Serono Sa Sulfonyl amino cyclic derivatives and use thereof
JP4950070B2 (ja) 2005-01-31 2012-06-13 メルク セローノ ソシエテ アノニム Ｎ−ヒドロキシアミド誘導体及びその使用
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
KR20080044836A (ko) * 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
AU2006332680A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007141224A2 (en) * 2006-06-02 2007-12-13 Laboratoires Serono Sa Jnk inhibitors for treatment of skin diseases
CN101541522B (zh) * 2006-08-28 2012-07-18 丹塞姆空气调节有限公司 用于制造热交换器的方法
AU2008216748A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
WO2010019606A1 (en) * 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
EP2346856A1 (de) 2008-09-29 2011-07-27 Telik, Inc. 2-[1h-benzimidazol-2(3h)-yliden]-2-(pyrimidin-2-yl)acetamide und 2-[benzothiazol-2(3h)-yliden]-2-(pyrimidin-2-yl)acetamide als kinaseinhibitoren
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
CN102199147A (zh) * 2011-03-19 2011-09-28 陕西合成药业有限公司 用于治疗的硝基咪唑衍生物
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
EP3082422A4 (de) * 2013-12-20 2017-07-05 Biomed Valley Discoveries, Inc. Krebsbehandlungen unter verwendung von kombinationen aus typ-1-mek- und -erk-hemmern
KR101520378B1 (ko) * 2014-10-02 2015-05-26 (주)에프테크 습식 가스 스크러버의 배기유도장치
WO2016055517A1 (en) * 2014-10-08 2016-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel aminopyridine compounds useful as inhibitors of protein prenylation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918369A (en) * 1956-06-15 1959-12-22 Gen Aniline & Film Corp Non-ionic benzimidazole cyanine dyes containing in alpha-position a cyano group on the methenyl chain
GB864131A (en) * 1957-07-17 1961-03-29 Ciba Ltd Benzimidazolyl-acetic acid derivatives
DE1963542A1 (de) 1969-12-18 1971-06-24 Siemens Ag Koppelfeldanordnung fuer Fernmelde-,insbesondere Fernsprechanlagen
JPS51123223A (en) * 1975-04-21 1976-10-27 Fuji Photo Film Co Ltd Process for producing condensation products
CH593954A5 (de) * 1975-07-21 1977-12-30 Ciba Geigy Ag
EP0364765A3 (de) * 1988-10-08 1991-07-17 Bayer Ag Substituierte 1,3,5-Triazintrione, Verfahren zu ihrer Herstellung und ihre Verwendung gegen parasitäre Protozoen
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine

Also Published As

Publication number Publication date
EE200200318A (et) 2003-10-15
EP1110957A1 (de) 2001-06-27
ES2206351T3 (es) 2004-05-16
BG106830A (bg) 2003-02-28
US7470686B2 (en) 2008-12-30
US20030162794A1 (en) 2003-08-28
EA200200708A1 (ru) 2003-02-27
CN1252067C (zh) 2006-04-19
CZ20022169A3 (cs) 2002-09-11
SK8982002A3 (en) 2002-10-08
SI1240164T1 (en) 2004-04-30
IL150346A (en) 2010-12-30
KR20020072282A (ko) 2002-09-14
JP2003519142A (ja) 2003-06-17
BR0016911A (pt) 2002-10-22
US7259162B2 (en) 2007-08-21
BG65986B1 (bg) 2010-08-31
PT1240164E (pt) 2004-02-27
EA007152B1 (ru) 2006-08-25
HRP20020496A2 (en) 2006-03-31
HRP20020496B1 (en) 2009-03-31
RS51008B (sr) 2010-10-31
CZ300984B6 (cs) 2009-09-30
US20070259892A1 (en) 2007-11-08
NZ519423A (en) 2004-04-30
WO2001047920A1 (en) 2001-07-05
HUP0204557A3 (en) 2009-03-30
ATE254123T1 (de) 2003-11-15
EP1240164A1 (de) 2002-09-18
MXPA02006242A (es) 2003-01-28
EP1240164B1 (de) 2003-11-12
JP4782344B2 (ja) 2011-09-28
TR200302320T4 (tr) 2004-01-21
PL356634A1 (en) 2004-06-28
HU229625B1 (hu) 2014-03-28
AU780241B2 (en) 2005-03-10
AR029215A1 (es) 2003-06-18
TR200201509T2 (tr) 2002-09-23
KR20070047853A (ko) 2007-05-07
CN1433414A (zh) 2003-07-30
EE05456B1 (et) 2011-08-15
CA2394809C (en) 2011-03-15
KR100736012B1 (ko) 2007-07-06
CA2394809A1 (en) 2001-07-05
IL150346A0 (en) 2002-12-01
AU3161601A (en) 2001-07-09
NO20022997L (no) 2002-06-21
HUP0204557A2 (en) 2003-05-28
SK287546B6 (sk) 2011-01-04
ZA200204427B (en) 2004-02-03
YU49202A (sh) 2006-01-16
UA73151C2 (en) 2005-06-15
DK1240164T3 (da) 2004-03-01
HK1055730A1 (en) 2004-01-21
DE60006580T2 (de) 2004-09-16
NO323146B1 (no) 2007-01-08
NO20022997D0 (no) 2002-06-21

Similar Documents

Publication Publication Date Title
ATE254123T1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE252091T1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE59710580D1 (de) Thiocyano-triazolyl-derivate und ihre verwendung als mikrobizide
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
DE60322551D1 (de) 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren
ATE247109T1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE69902387D1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
DE60009911D1 (de) Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60116732D1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
DE69917777D1 (de) Benzazol-verbindungen und ihre verwendung
ATE229016T1 (de) Substituierte heterocyclische benzocycloalkene und ihre verwendung als analgetisch wirksame substanzen
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE60316134D1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
DE60008539D1 (de) Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH